AustralieFrV1, Main, Exploration, bibRecord, 005A05

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib

Identifieur interne : 005A05 ( Main/Exploration ); précédent : 005A04; suivant : 005A06

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib

Auteurs : P. Reichardt [Allemagne] ; J.-Y. Blay [France] ; H. Gelderblom [Pays-Bas] ; M. Schlemmer [Allemagne] ; G. D. Demetri [États-Unis] ; B. Bui-Nguyen [France] ; G. A. Mcarthur [Australie] ; S. Yazji [États-Unis] ; Y. Hsu [États-Unis] ; I. Galetic [Suisse] ; P. Rutkowski [Pologne]

Source :

Annals of oncology [ 0923-7534 ] ; 2012.

RBID : Pascal:12-0298222

Descripteurs français

Pascal (Inist)
- Homme, Essai clinique phase III, Traitement, Nilotinib, Etude comparative, Soin de support, Malade, Tumeur stromale gastro-intestinale, Résistance, Imatinib, Sunitinib, Inhibiteur enzyme, Protein-tyrosine kinase, Inhibiteur de la tyrosine kinase, Anticancéreux, Antiangiogénique.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiangiogenic agent, Antineoplastic agent, Comparative study, Enzyme inhibitor, Gastrointestinal stromal tumor, Human, Imatinib, Nilotinib, Patient, Phase III trial, Protein-tyrosine kinase, Resistance, Sunitinib, Supportive care, Treatment, Tyrosine kinase inhibitor.

Abstract

Background: This phase III open-label trial investigated the efficacy of nilotinib in patients with advanced gastrointestinal stromal tumors following prior imatinib and sunitinib failure. Patients and methods: Patients were randomized 2: 1 to nilotinib 400 mg b.i.d. or best supportive care (BSC; BSC without tyrosine kinase inhibitor, BSC + imatinib, or BSC + sunitinib). Primary efficacy end point was progression-free survival (PFS) based on blinded central radiology review (CRR). Patients progressing on BSC could cross over to nilotinib. Results: Two hundred and forty-eight patients enrolled. Median PFS was similar between arms (nilotinib 109 days, BSC 111 days; P = 0.56). Local investigator-based intent-to-treat (ITT) analysis showed a significantly longer median PFS with nilotinib (119 versus 70 days; P = 0.0007). A trend in longer median overall survival (OS) was noted with nilotinib (332 versus 280 days; P = 0.29). Post hoc subset analyses in patients with progression and only one prior regimen each of imatinib and sunitinib revealed a significant difference in median OS of >4 months in favor of nilotinib (405 versus 280 days; P = 0.02). Nilotinib was well tolerated. Conclusion: In the ITT analysis, no significant difference in PFS was observed between treatment arms based on CRR. In the post hoc subset analyses, nilotinib provided significantly longer median OS.

Affiliations:

Allemagne, Australie, France, Pays-Bas, Pologne, Suisse, États-Unis
Aquitaine, Auvergne-Rhône-Alpes, Bavière, District de Haute-Bavière, Hollande-Méridionale, Massachusetts, Nouvelle-Aquitaine, Rhône-Alpes, Victoria (État)
Bordeaux, Boston, Leyde, Lyon, Melbourne, Munich

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001235
to stream PascalFrancis, to step Curation: 004C82
to stream PascalFrancis, to step Checkpoint: 000E64
to stream Main, to step Merge: 005C99
to stream Main, to step Curation: 005A05

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib</title>
<author><name sortKey="Reichardt, P" sort="Reichardt, P" uniqKey="Reichardt P" first="P." last="Reichardt">P. Reichardt</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>HELIOS Klinikum Bad Saarow, Sarkomzentrum Berlin-Brandenburg</s1>
<s2>Bad Saarow</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bad Saarow</wicri:noRegion>
<wicri:noRegion>Sarkomzentrum Berlin-Brandenburg</wicri:noRegion>
<wicri:noRegion>Bad Saarow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Blay, J Y" sort="Blay, J Y" uniqKey="Blay J" first="J.-Y." last="Blay">J.-Y. Blay</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Leon Bérar Comprehensive Cancer Centre, Université Claude Bernard Lyon I</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gelderblom, H" sort="Gelderblom, H" uniqKey="Gelderblom H" first="H." last="Gelderblom">H. Gelderblom</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Clinical Oncology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schlemmer, M" sort="Schlemmer, M" uniqKey="Schlemmer M" first="M." last="Schlemmer">M. Schlemmer</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Internal Medicine III, University Hospitals Grosshadern, Ludwig Maximilians University Munich</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Demetri, G D" sort="Demetri, G D" uniqKey="Demetri G" first="G. D." last="Demetri">G. D. Demetri</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Center for Sarcoma and Bone Oncology, Ludwig Center at Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute</s1>
<s2>Boston</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Boston</settlement>
<region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bui Nguyen, B" sort="Bui Nguyen, B" uniqKey="Bui Nguyen B" first="B." last="Bui-Nguyen">B. Bui-Nguyen</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Institut Bergonié</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G. A." last="Mcarthur">G. A. Mcarthur</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Division of Cancer Medicine, Peter MacCallum Cancer Center</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yazji, S" sort="Yazji, S" uniqKey="Yazji S" first="S." last="Yazji">S. Yazji</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>Florham Park</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Novartis Pharmaceuticals Corporation</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hsu, Y" sort="Hsu, Y" uniqKey="Hsu Y" first="Y." last="Hsu">Y. Hsu</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>Florham Park</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Novartis Pharmaceuticals Corporation</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Galetic, I" sort="Galetic, I" uniqKey="Galetic I" first="I." last="Galetic">I. Galetic</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Novartis Pharma AG</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>Novartis Pharma AG</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rutkowski, P" sort="Rutkowski, P" uniqKey="Rutkowski P" first="P." last="Rutkowski">P. Rutkowski</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Soft Tissue/Bone Sarcoma and Melanoma, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology</s1>
<s2>Warsaw</s2>
<s3>POL</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Pologne</country>
<wicri:noRegion>Warsaw</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0298222</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0298222 INIST</idno>
<idno type="RBID">Pascal:12-0298222</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001235</idno>
<idno type="wicri:Area/PascalFrancis/Curation">004C82</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000E64</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000E64</idno>
<idno type="wicri:doubleKey">0923-7534:2012:Reichardt P:phase:iii:study</idno>
<idno type="wicri:Area/Main/Merge">005C99</idno>
<idno type="wicri:Area/Main/Curation">005A05</idno>
<idno type="wicri:Area/Main/Exploration">005A05</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib</title>
<author><name sortKey="Reichardt, P" sort="Reichardt, P" uniqKey="Reichardt P" first="P." last="Reichardt">P. Reichardt</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>HELIOS Klinikum Bad Saarow, Sarkomzentrum Berlin-Brandenburg</s1>
<s2>Bad Saarow</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bad Saarow</wicri:noRegion>
<wicri:noRegion>Sarkomzentrum Berlin-Brandenburg</wicri:noRegion>
<wicri:noRegion>Bad Saarow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Blay, J Y" sort="Blay, J Y" uniqKey="Blay J" first="J.-Y." last="Blay">J.-Y. Blay</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Leon Bérar Comprehensive Cancer Centre, Université Claude Bernard Lyon I</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gelderblom, H" sort="Gelderblom, H" uniqKey="Gelderblom H" first="H." last="Gelderblom">H. Gelderblom</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Clinical Oncology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schlemmer, M" sort="Schlemmer, M" uniqKey="Schlemmer M" first="M." last="Schlemmer">M. Schlemmer</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Internal Medicine III, University Hospitals Grosshadern, Ludwig Maximilians University Munich</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Demetri, G D" sort="Demetri, G D" uniqKey="Demetri G" first="G. D." last="Demetri">G. D. Demetri</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Center for Sarcoma and Bone Oncology, Ludwig Center at Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute</s1>
<s2>Boston</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Boston</settlement>
<region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bui Nguyen, B" sort="Bui Nguyen, B" uniqKey="Bui Nguyen B" first="B." last="Bui-Nguyen">B. Bui-Nguyen</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Institut Bergonié</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G. A." last="Mcarthur">G. A. Mcarthur</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Division of Cancer Medicine, Peter MacCallum Cancer Center</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yazji, S" sort="Yazji, S" uniqKey="Yazji S" first="S." last="Yazji">S. Yazji</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>Florham Park</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Novartis Pharmaceuticals Corporation</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hsu, Y" sort="Hsu, Y" uniqKey="Hsu Y" first="Y." last="Hsu">Y. Hsu</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>Florham Park</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Novartis Pharmaceuticals Corporation</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Galetic, I" sort="Galetic, I" uniqKey="Galetic I" first="I." last="Galetic">I. Galetic</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Novartis Pharma AG</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>Novartis Pharma AG</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rutkowski, P" sort="Rutkowski, P" uniqKey="Rutkowski P" first="P." last="Rutkowski">P. Rutkowski</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Soft Tissue/Bone Sarcoma and Melanoma, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology</s1>
<s2>Warsaw</s2>
<s3>POL</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Pologne</country>
<wicri:noRegion>Warsaw</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiangiogenic agent</term>
<term>Antineoplastic agent</term>
<term>Comparative study</term>
<term>Enzyme inhibitor</term>
<term>Gastrointestinal stromal tumor</term>
<term>Human</term>
<term>Imatinib</term>
<term>Nilotinib</term>
<term>Patient</term>
<term>Phase III trial</term>
<term>Protein-tyrosine kinase</term>
<term>Resistance</term>
<term>Sunitinib</term>
<term>Supportive care</term>
<term>Treatment</term>
<term>Tyrosine kinase inhibitor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Homme</term>
<term>Essai clinique phase III</term>
<term>Traitement</term>
<term>Nilotinib</term>
<term>Etude comparative</term>
<term>Soin de support</term>
<term>Malade</term>
<term>Tumeur stromale gastro-intestinale</term>
<term>Résistance</term>
<term>Imatinib</term>
<term>Sunitinib</term>
<term>Inhibiteur enzyme</term>
<term>Protein-tyrosine kinase</term>
<term>Inhibiteur de la tyrosine kinase</term>
<term>Anticancéreux</term>
<term>Antiangiogénique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: This phase III open-label trial investigated the efficacy of nilotinib in patients with advanced gastrointestinal stromal tumors following prior imatinib and sunitinib failure. Patients and methods: Patients were randomized 2: 1 to nilotinib 400 mg b.i.d. or best supportive care (BSC; BSC without tyrosine kinase inhibitor, BSC + imatinib, or BSC + sunitinib). Primary efficacy end point was progression-free survival (PFS) based on blinded central radiology review (CRR). Patients progressing on BSC could cross over to nilotinib. Results: Two hundred and forty-eight patients enrolled. Median PFS was similar between arms (nilotinib 109 days, BSC 111 days; P = 0.56). Local investigator-based intent-to-treat (ITT) analysis showed a significantly longer median PFS with nilotinib (119 versus 70 days; P = 0.0007). A trend in longer median overall survival (OS) was noted with nilotinib (332 versus 280 days; P = 0.29). Post hoc subset analyses in patients with progression and only one prior regimen each of imatinib and sunitinib revealed a significant difference in median OS of >4 months in favor of nilotinib (405 versus 280 days; P = 0.02). Nilotinib was well tolerated. Conclusion: In the ITT analysis, no significant difference in PFS was observed between treatment arms based on CRR. In the post hoc subset analyses, nilotinib provided significantly longer median OS.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>France</li>
<li>Pays-Bas</li>
<li>Pologne</li>
<li>Suisse</li>
<li>États-Unis</li>
</country>
<region><li>Aquitaine</li>
<li>Auvergne-Rhône-Alpes</li>
<li>Bavière</li>
<li>District de Haute-Bavière</li>
<li>Hollande-Méridionale</li>
<li>Massachusetts</li>
<li>Nouvelle-Aquitaine</li>
<li>Rhône-Alpes</li>
<li>Victoria (État)</li>
</region>
<settlement><li>Bordeaux</li>
<li>Boston</li>
<li>Leyde</li>
<li>Lyon</li>
<li>Melbourne</li>
<li>Munich</li>
</settlement>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Reichardt, P" sort="Reichardt, P" uniqKey="Reichardt P" first="P." last="Reichardt">P. Reichardt</name>
</noRegion>
<name sortKey="Schlemmer, M" sort="Schlemmer, M" uniqKey="Schlemmer M" first="M." last="Schlemmer">M. Schlemmer</name>
</country>
<country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Blay, J Y" sort="Blay, J Y" uniqKey="Blay J" first="J.-Y." last="Blay">J.-Y. Blay</name>
</region>
<name sortKey="Bui Nguyen, B" sort="Bui Nguyen, B" uniqKey="Bui Nguyen B" first="B." last="Bui-Nguyen">B. Bui-Nguyen</name>
</country>
<country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Gelderblom, H" sort="Gelderblom, H" uniqKey="Gelderblom H" first="H." last="Gelderblom">H. Gelderblom</name>
</region>
</country>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Demetri, G D" sort="Demetri, G D" uniqKey="Demetri G" first="G. D." last="Demetri">G. D. Demetri</name>
</region>
<name sortKey="Hsu, Y" sort="Hsu, Y" uniqKey="Hsu Y" first="Y." last="Hsu">Y. Hsu</name>
<name sortKey="Yazji, S" sort="Yazji, S" uniqKey="Yazji S" first="S." last="Yazji">S. Yazji</name>
</country>
<country name="Australie"><region name="Victoria (État)"><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G. A." last="Mcarthur">G. A. Mcarthur</name>
</region>
</country>
<country name="Suisse"><noRegion><name sortKey="Galetic, I" sort="Galetic, I" uniqKey="Galetic I" first="I." last="Galetic">I. Galetic</name>
</noRegion>
</country>
<country name="Pologne"><noRegion><name sortKey="Rutkowski, P" sort="Rutkowski, P" uniqKey="Rutkowski P" first="P." last="Rutkowski">P. Rutkowski</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005A05 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005A05 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:12-0298222
   |texte=   Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri